What top creators are saying about Biohaven Ltd.(BHVN)

Mentioned among biotech fund holdings; no company-specific investment analysis was provided.

The speaker said he had too many thoughts on Biohaven but did not explain them, leaving no actionable investment view.

Upcoming obesity data were mentioned, with speculation that they might relate to a myostatin program. No result, date, or investment view was provided.

Mentioned in connection with upcoming obesity data that the speaker thought might involve a myostatin program; no results outlook or recommendation was offered.

Shkreli said Biohaven would be a good one to look at but offered no thesis, catalyst, or directional view.

The speaker said Biohaven would be a good company to look at, but provided no investment thesis.

Reportedly completed a deal involving $80 million upfront, but the counterparty, terms, and payment direction were not identified.

The company announced a deal with $80 million upfront, but the discussion gave no clear stock view or sufficient deal context to assess its valuation impact.

The speaker said he liked Biohaven but provided no supporting rationale or valuation view.

Bullish long-term outlook backed by strong confidence in management's historical capital allocation ability and track record of shareholder value creation.

Host likes Biohaven, readouts coming soon, pre-catalyst pharma play with upcoming clinical data.

Regarded as a strong long-term 'management pick' within the biotech sector.

Noted for having good management within the biotech/rare disease strategy.

Described as a 'high-quality company with smart management and good assets,' indicating a generally positive and bullish view.

The speaker is long but calls its performance 'dog poopoo'. The slight bullishness comes from insider buying in a secondary offering, which is seen as a positive sign that the 'worst is over'.

It is the speaker's second biggest long position due to strong insider confidence, as major shareholders and board members participated heavily in a recent deal.

The stock price fell after the company announced a $150 million stock sale, which dilutes the ownership stake for existing shareholders.

The speaker is long, believing the company has strong support from Wall Street ("a lot of fans") and easy access to capital.

Long-term bullish, actively buying more shares based on the strength of the CEO, despite short-term headwinds from an FDA Complete Response Letter (CRL) and an expected financing.

The speaker is very bullish, stating it is his 'biggest position' and is holding it with strong conviction through a market downturn.

Speaker has gone 'all in' with an 80% position, viewing the stock as unfairly punished after an expected FDA rejection. Believes the market overreacted and long-term supporters will cause the price to recover.

A high-risk, high-reward biotech stock centered around a near-term FDA decision. The speaker suggests it could be a 'buy a little here' situation, viewing it as a good long-term hold due to strong management, even if the lead drug fails.

Listed as one of the biotech/pharma companies the speaker holds positive views on and/or has positions in.

Held as a long position and bullish bet in the speaker's personal trading account.